Great news from Algiax – our peer-reviewed publication on one of our novel positive allosteric modulators of the GABAA-receptor, the thioacrylamide HK4, is now available openly at the Journal Diabetes Obesity and Metabolism. The publication gives further insights in how HK4 protects human hepatocytes against lipotoxicity-induced injury by preventing inflammation, DNA damage and ER stress. The data provided hints that this compound is an innovative pharmacological tool to treat non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). To check out the full publication click here